Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide - Wikidata - wikimedia - TriplyDB

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

http://www.wikidata.org/entity/Q34428697

about

Medical treatment for gastro-entero-pancreatic neuroendocrine tumours Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Do we really care about incidental lung nodules?-Review of atypical lung carcinoid and a proposal for systematic patient follow up Update on management of midgut neuroendocrine tumors.Refractory carcinoid syndrome: a review of treatment options.Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.Ileal neuroendocrine tumors and heart: not only valvular consequences.Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.Telotristat ethyl: a new option for the management of carcinoid syndrome.Clinical signs of fibrosis in small intestinal neuroendocrine tumours.Carcinoid heart disease: a guide for screening and timing of surgical intervention Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.May depressed and anxious patients with carcinoid syndrome benefit from treatment with selective serotonin reuptake inhibitors (SSRIs)?: findings from a case report.Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.Update in the Therapy of Advanced Neuroendocrine Tumors.Carcinoid-syndrome: recent advances, current status and controversies.Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation.Telotristat Ethyl: First Global Approval.Developments in the treatment of carcinoid syndrome - impact of telotristat.Carcinoid syndrome: update on the pathophysiology and treatment

P2860

Q26751659-8A9B6BCB-1DE3-4472-98EC-6CE93B9A1CF1 Q28078610-58A4F372-B923-4D6F-9E9C-D7CFD46BB194 Q30364864-DF1C5A30-A910-4EFB-B192-F065D25F9627 Q33639498-9C1F323F-E618-481A-8FE8-3C6D33FB3723 Q33737587-F4091E87-A4BD-4114-BC6C-4ED1276ECFB9 Q33890530-BCFB6560-2261-4702-930C-2177D251F1D7 Q37025143-221C6796-EC91-4C0E-8B17-E75B20A8DB77 Q37632161-8A3F092F-540D-40D8-A542-77A3000F8AE4 Q37698605-9F1F566E-51E7-4A35-8873-49888E9ECB57 Q38260542-13C8D6D5-168F-4C73-9707-8381CAA2ECC6 Q38815549-045B618F-5633-478A-93CE-36F0E0A2C396 Q39000212-83FEF1F5-B4AC-4BC1-8990-55CA95BB4D59 Q39175786-56E653F4-B838-49E8-BBF3-F91C949B8336 Q39385108-1DE3A1E7-2A87-4796-AF3E-BB3A6A33AE94 Q42053148-DB8E0901-3A56-47CA-9862-6F45D45BB7EC Q47431595-46EB27E5-B65F-4F17-B88C-EE08E4C617B7 Q47724538-F3055FCB-EA7E-4A17-AB70-3EC2FDF30667 Q47886895-D0350D7A-4B03-417A-9012-3A1D5ABFAD01 Q47944297-B375287C-FEC5-4531-AC2C-30354368CCF9 Q49970741-6D9C7A9C-A4E8-4BE6-96AC-247D7354267E Q50094023-95EBAAC9-0F1A-440A-A7ED-868752363655 Q50952188-32F72F5C-C82B-42EB-86D9-9BA9E7AA67E4 Q51069551-D431737A-1BC4-433C-997A-214964E0FF45 Q52674898-D0E03278-3EFA-46E5-883A-59860983C40B Q58801185-773BFCD0-19C4-47D0-AF3B-4526867A1FE9

P2860

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide

http://www.wikidata.org/entity/Q34428697

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Telotristat etiprate, a novel ...... ately controlled by octreotide

@ast

Telotristat etiprate, a novel ...... ately controlled by octreotide

@en

Telotristat etiprate, a novel ...... ately controlled by octreotide

@nl

type

label

Telotristat etiprate, a novel ...... ately controlled by octreotide

@ast

Telotristat etiprate, a novel ...... ately controlled by octreotide

@en

Telotristat etiprate, a novel ...... ately controlled by octreotide

@nl

prefLabel

Telotristat etiprate, a novel ...... ately controlled by octreotide

@ast

Telotristat etiprate, a novel ...... ately controlled by octreotide

@en

Telotristat etiprate, a novel ...... ately controlled by octreotide

@nl

P1433

Q34428697-61B04F71-2A99-48C4-9B03-6AFADEC6947D

P1476

Q34428697-2F45AA14-BEA9-43AD-A9EE-3DE2348BC062

P2093

Q34428697-315E9A61-40A7-4B26-8B57-18BFAF590D7E

Q34428697-40646332-980A-4841-BF38-8D116DDB249D

Q34428697-43CEE9AE-F0BC-4671-892D-EA27BDDC461E

Q34428697-46F48446-BF6B-440A-AB8F-7A51A7413AE8

Q34428697-63ECEB49-A678-40DA-8C56-FB3354939434

Q34428697-7024B1AA-C3C5-4B2D-A390-06BB4BB2E930

Q34428697-75DB21DF-DBFA-4BE3-8CFA-C1BDF3F00AC5

Q34428697-7A872BDB-4466-4EFE-BB18-43C05B36D993

Q34428697-867918FA-0B2C-434B-954A-2DA0799A1123

Q34428697-88BDA62F-DA81-4CC9-84CD-929802DB4506

P2860

Q34428697-17504D00-57D2-4AE6-B044-AA93BD54957A

Q34428697-6168B66F-FE92-40D9-8845-16E6BC400989

Q34428697-98FF8A5E-1913-4705-9A76-12CB215C0F9D

Q34428697-9A4280CF-AFC1-4838-87E0-AB8F2372C376

Q34428697-A412766A-1280-405D-865D-546627C5261C

Q34428697-E7C3317F-149F-4424-AA47-262F0FC606FB

Q34428697-EEEADD7C-B994-4F35-82D8-22F605734121

Q34428697-EF2E4DB1-E994-445C-835C-BC067E100EF7

Q34428697-F1284006-EB65-4DBC-806A-4AC7908DB358

P304

Q34428697-4C2E3D31-21FD-43D3-BF84-C40E4A6B3C4C

P31

Q34428697-1AF9E34B-2C08-4D3F-A16D-B31D33C6BD06

P356

Q34428697-31482945-DB19-4571-9C14-8313EE2E394E

P433

Q34428697-155EBF71-F427-457C-8076-9B238A949CE8

P478

Q34428697-9EDD9622-B732-4B68-B150-EB6D6E20F191

P50

Q34428697-3FBB1124-F60C-4AD7-B5CE-F4D1D45B6A84

P577

Q34428697-DD750CBC-F766-4442-8EA4-8EBEF429B93F

P5875

Q34428697-7D37B3E4-D782-4C17-B1DA-2F73B8C0912A

P698

Q34428697-5E160797-4D32-429A-8DD0-847DB4F5DFC8

P921

Q34428697-1fe60e54-d297-40eb-80af-b997287a03f9

Q34428697-B7F8DEE2-4031-430E-8514-68E4950C3791

P932

Q34428697-C15259A4-3106-4EF2-AF7B-95D4603E09C8

P356

P1433

Endocrine-related cancer

P1476

Telotristat etiprate, a novel ...... ately controlled by octreotide

@en

P2093

Alexandria Phan

http://www.w3.org/2001/XMLSchema#string

Arthur Sands

http://www.w3.org/2001/XMLSchema#string

Brian Zambrowicz

http://www.w3.org/2001/XMLSchema#string

Douglas Fleming

http://www.w3.org/2001/XMLSchema#string

Emily Bergsland

http://www.w3.org/2001/XMLSchema#string

James C Yao

http://www.w3.org/2001/XMLSchema#string

Jessica Jackson

http://www.w3.org/2001/XMLSchema#string

Joel Freiman

http://www.w3.org/2001/XMLSchema#string

Kenny Frazier

http://www.w3.org/2001/XMLSchema#string

Larry Kvols

http://www.w3.org/2001/XMLSchema#string

P2860

Valvular heart disease associated with fenfluramine-phentermine

Long-term serotonin administration induces heart valve disease in rats.

Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.

Fibrosis and carcinoid syndrome: from causation to future therapy.

The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study

Carcinoid tumors: development of our knowledge.

Factors associated with progression of carcinoid heart disease.

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population.

P304

705-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-14-0173

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Thomas O'Dorisio

P577

2014-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263863562

http://www.w3.org/2001/XMLSchema#string

P698

25012985

http://www.w3.org/2001/XMLSchema#string

P921

Afọ ọsịsa

P932

4295770

http://www.w3.org/2001/XMLSchema#string